S&P TSX Capped Composite...

US Dollar vs CAD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

Home
Investing
Stocks
USA
NASDAQ
IDEAYA Biosciences Inc (IDYA)
IDEAYA Biosciences Inc (IDYA) News

IDYA

IDEAYA Biosciences (IDYA)

IDEAYA Biosciences Inc

Date:

Regulatory News

Text Search:

Sort by:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:IDYA

1 2 3 4 5 6 7 8 9 10 Next >>

Date	Time	Source	Headline	Symbol	Company
07/10/2024	4:17PM	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:IDYA	IDEAYA Biosciences Inc
07/09/2024	9:26PM	PR Newswire (US)	IDEAYA Announces Pricing of Public Offering	NASDAQ:IDYA	IDEAYA Biosciences Inc
07/09/2024	4:08PM	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:IDYA	IDEAYA Biosciences Inc
07/09/2024	3:11PM	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:IDYA	IDEAYA Biosciences Inc
07/09/2024	3:08PM	PR Newswire (US)	IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants	NASDAQ:IDYA	IDEAYA Biosciences Inc
07/08/2024	5:37AM	IH Market News	Paramount-Skydance $28B Merger, Boeing Agrees to Plead Guilty with $243.6M Fine, and More News	NASDAQ:IDYA	IDEAYA Biosciences Inc
07/08/2024	5:04AM	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:IDYA	IDEAYA Biosciences Inc
07/08/2024	5:00AM	PR Newswire (US)	IDEAYA Announces Positive Interim Phase 2 Monotherapy Expansion Data for IDE397 a Potential First-in-Class MAT2A Inhibitor in MTAP-Deletion Urothelial and Lung Cancer	NASDAQ:IDYA	IDEAYA Biosciences Inc
07/05/2024	3:05PM	PR Newswire (US)	IDEAYA Announces Investor Webcast to Report Clinical Data Update for IDE397 Phase 2 Monotherapy Expansion Dose in MTAP-Deletion Urothelial and Lung Cancer on Monday, July 8, 2024	NASDAQ:IDYA	IDEAYA Biosciences Inc
06/28/2024	5:00AM	PR Newswire (US)	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:IDYA	IDEAYA Biosciences Inc
06/25/2024	5:00AM	PR Newswire (US)	IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy® Combination in MTAP-Deletion Bladder Cancer	NASDAQ:IDYA	IDEAYA Biosciences Inc
06/24/2024	5:00AM	PR Newswire (US)	IDEAYA Biosciences Announces Clinical Program Updates for IDE397 a Potential First-in-Class Phase 2 MAT2A Inhibitor Targeting MTAP-Deletion Solid Tumors	NASDAQ:IDYA	IDEAYA Biosciences Inc
06/03/2024	5:05AM	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:IDYA	IDEAYA Biosciences Inc
06/03/2024	5:00AM	PR Newswire (US)	IDEAYA Announces Results for Darovasertib Phase 2 IST in Neoadjuvant Uveal Melanoma at ASCO and Clinical Update for Phase 2 Company-Sponsored Neoadjuvant Study	NASDAQ:IDYA	IDEAYA Biosciences Inc
05/31/2024	3:54PM	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:IDYA	IDEAYA Biosciences Inc
05/31/2024	3:38PM	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IDYA	IDEAYA Biosciences Inc
05/31/2024	3:26PM	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IDYA	IDEAYA Biosciences Inc
05/31/2024	5:00AM	PR Newswire (US)	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:IDYA	IDEAYA Biosciences Inc
05/29/2024	4:02PM	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:IDYA	IDEAYA Biosciences Inc
05/29/2024	5:00AM	PR Newswire (US)	IDEAYA Biosciences to Participate in Upcoming June 2024 Investor Relations Events	NASDAQ:IDYA	IDEAYA Biosciences Inc
05/28/2024	5:00AM	PR Newswire (US)	IDEAYA Biosciences Appoints Daniel A. Simon as Chief Business Officer to Lead Corporate Strategy and Business Development	NASDAQ:IDYA	IDEAYA Biosciences Inc
05/23/2024	8:21PM	PR Newswire (US)	/C O R R E C T I O N -- IDEAYA Biosciences, Inc./	NASDAQ:IDYA	IDEAYA Biosciences Inc
05/23/2024	4:05PM	PR Newswire (US)	IDEAYA Biosciences Announces Abstract Summary Results of ASCO 2024 Oral Presentation for Phase 2 Investigator Sponsored Study of Darovasertib in Neoadjuvant Uveal Melanoma	NASDAQ:IDYA	IDEAYA Biosciences Inc
05/07/2024	5:04AM	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:IDYA	IDEAYA Biosciences Inc
05/07/2024	5:00AM	PR Newswire (US)	IDEAYA Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update	NASDAQ:IDYA	IDEAYA Biosciences Inc
05/01/2024	5:00AM	PR Newswire (US)	IDEAYA Biosciences to Participate in Upcoming May 2024 Investor Relations Event	NASDAQ:IDYA	IDEAYA Biosciences Inc
04/26/2024	5:00AM	PR Newswire (US)	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:IDYA	IDEAYA Biosciences Inc
04/24/2024	9:05AM	PR Newswire (US)	IDEAYA Biosciences Announces ASCO 2024 Oral Presentation for Darovasertib in Neoadjuvant Uveal Melanoma Phase 2 Investigator Sponsored Study	NASDAQ:IDYA	IDEAYA Biosciences Inc
04/22/2024	5:00AM	PR Newswire (US)	IDEAYA Biosciences Announces Selection of Move-Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous Non-Small Cell Lung Cancer	NASDAQ:IDYA	IDEAYA Biosciences Inc
04/05/2024	5:00AM	PR Newswire (US)	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:IDYA	IDEAYA Biosciences Inc

Showing the most relevant articles for your search:NASDAQ:IDYA

1 2 3 4 5 6 7 8 9 10 Next >>

Asia Broadband (PK)

Seafarer Exploration (PK)

Moon Equity (PK)

Code Green Apparel (PK)

Maxeon Solar Technologies

FuelCell Energy

Ronn Motor (PK)

Progressive Care (QB)

TPT Global Tech (PK)

Impact Fusion (PK)

Bioelectronics (PK)

Elite Pharmaceuticals (QB)

Rennova Health (PK)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions